Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

Novo Nordisk (NVO), which develops weight-loss drugs, looks poised to perform well over the short term, Rebecca Walser, the ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

As CMS maintains limits on GLP-1 coverage for weight loss, new efficacy data and shifting prescribing patterns point to sustained high demand across the drug class. Here are four updates: 1. Federal ...

Health-care companies slid after signs of stress in UnitedHealth Group's business. The largest U.S. insurer by enrollees cut its growth projections, citing hitches with its key Medicare business.

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...